June 12 – 17, 2022
Spike glycoprotein (S) and its Receptor Binding Domain region (RBD) are the main targets of neutralizing antibodies during an infection with SARS-CoV-2, the etiologic agent of COVID-19 pandemic viral disease. Thus, they are the chosen antigens for the development of diagnostic kits and vaccines candidates. Furthermore, Virus-like Particles (VLPs) constitute potent immunogens that have been engineered to obtain vaccine candidates through expression of SARS-CoV-2 S, M, E and N proteins. Although it might be a challenging platform, as multiple proteins must be expressed in order to assure VLP budding, they are able to induce stronger immune responses than soluble antigens due to their particulate nature and highly repetitive antigen display. Hence, we aimed to generate a serum-free platform to produce soluble SARS-CoV-2 antigens and design a novel chimeric VLP (cVLP) exposing the prefusion stabilized S ectodomain on its surface.
Please click Download on the upper right corner to see the full abstract.
Claudio Prieto, Ernesto Garay, Javier Villarraza, Antonela Fuselli, Agustina Gugliotta, Celeste Rodríguez, Victoria Gastaldi, Natalia Ceaglio, and Diego Fontana, "Protein design and immunogenic analysis of COVID-19 vaccine candidates based on RBD/trimeric-spike antigens and chimeric VLPs antigens" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/107